All In Biotech

Drug Trial Radar · NCT07871890

A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 1b/2a, Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Activity of Small Mobile Stem Cells (SMS) Delivered Into the Lung as a Potential Organ Regeneration Therapy in Moderate to Severe Chronic Obstructive Pulmonary Disease (SORT-COPD Study II)

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Lead sponsor
SMSbiotechIndustry
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 1b/2a, open-label, non-randomized, observation of 125 adults, with moderate to severe chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells). The primary objective of this study is to evaluate the preliminary within-participant changes of SORT-COPD (SMS cells), in suspension, delivered to the lung as an aerosolized mist via a vibrating mesh nebulizer, on respiratory health status in participants with moderate to severe chronic obstructive pulmonary disease.

Conditions

  • Chronic Obstructive Lung Disease

Interventions

  • Stem cellsBiological

    The suspension of Small Mobile Stem (SMS) cells will be placed into a medical nebulizer machine, commonly used to deliver medicines into the lungs through inhalation. Participants with moderate to severe chronic obstructive pulmonary disease (COPD) will breathe in the mist containing the SMS cells through a mouthpiece. The treatment will be given at the study site on Days 1, 3, and 6. Each treatment will contain 2.4 billion SMS cells and will take approximately 30 minutes to complete. This is a Phase 1b/2a study designed to evaluate the safety, tolerability, and potential effects of SMS cells in people with moderate to severe COPD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Baseline through 12 months
  2. Phase 1b: Dose-limiting toxicities (DLTs)Time frame: Baseline through Day 28
  3. Number of Participants With Clinically Significant Changes From Baseline in Hematology Laboratory ParametersTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  4. Number of Participants With Clinically Significant Changes From Baseline in Serum Chemistry Laboratory ParametersTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  5. Number of Participants With Clinically Significant ECG AbnormalitiesTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  6. Number of Participants With Clinically Significant Changes From Baseline in Systolic Blood PressureTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  7. Number of Participants With Clinically Significant Changes From Baseline in Diastolic Blood PressureTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  8. Number of Participants With Clinically Significant Changes From Baseline in Heart RateTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  9. Number of Participants With Clinically Significant Changes From Baseline in Respiratory RateTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  10. Number of Participants With Clinically Significant Changes From Baseline in Peripheral Oxygen SaturationTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  11. Number of Participants With Clinically Significant Abnormal Physical Examination FindingsTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  12. Number of Participants With Clinically Significant Changes From Baseline in Pre-Dose FEV1Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
  13. Number of Participants With Clinically Significant Changes From Pre-Dose to Post-Dose FEV1Time frame: Baseline, Day 28, 3 months, 6 months, 12 months
  14. Number of Participants With Clinically Significant Changes From Baseline in Pre-Dose FVCTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  15. Number of Participants With Clinically Significant Changes From Pre-Dose to Post-Dose FVCTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  16. Number of Participants With Treatment-Emergent Hypersensitivity ReactionsTime frame: Baseline, Day 28, 3 months, 6 months, 12 months
  17. Number of Participants With Treatment-Emergent Inhalation-Related ReactionsTime frame: Baseline, Day 28, 3 months, 6 months, 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.